Brazil health regulator authorizes clinical trials of Sanofi’s Covid-19 vaccine

ANVISA on Tuesday, July 6, authorized, the clinical trials in Brazil of Sanofi Pasteur's Covid-19 vaccine, which uses messenger RNA technology encapsulated inside a lipid nanoarticulation.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) on Tuesday, July 6, authorized clinical trials of Sanofi Pasteur's Covid-19 vaccine in Brazil. Trials will gather 150 volunteers over 18 years of age and will be conducted in the states of Bahia, Minas Gerais, Mato Grosso do Sul, and Rio de Janeiro.

The trial comprises phases 1 and 2 and will test three different dosages of the vaccine to determine the ideal dose before proceeding to a phase 3 trial, the last stage. It will entail two doses administered 21 days apart. A separate group of volunteers . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?